• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc. (Amendment)

    2/7/24 7:44:32 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FULC alert in real time by email
    SC 13G/A 1 p24-0425sc13ga.htm FULCRUM THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Fulcrum Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    359616109

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 35961610913G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,506,422

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,506,422

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,506,422

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.44%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

     

     

    CUSIP No. 35961610913G/APage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,506,422

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,506,422

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,506,422

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.44%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

     

    CUSIP No. 35961610913G/APage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,506,422

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,506,422

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,506,422

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.44%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

     

    CUSIP No. 35961610913G/APage 5 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,506,422

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,506,422

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,506,422

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.44%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

     

    CUSIP No. 35961610913G/APage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,506,422

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,506,422

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,506,422

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.44%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

     

    CUSIP No. 35961610913G/APage 7 of 10 Pages

     

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Fulcrum Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 26 Landsdowne Street, Cambridge, Massachusetts 02139.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:
       
      (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”) with respect to the Common Stock directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), as general partner of ACP with respect to the Common Stock directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), as managing member of ACPGP, general partner of ACP, with respect to the Common Stock directly owned by ACP;
       
      (iv) Robert Atchinson (“Mr. Atchinson”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock  directly owned by ACP; and
       
      (v) Phillip Gross (“Mr. Gross”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock directly owned by ACP.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       Common stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      359616109

     

     

    CUSIP No. 35961610913G/APage 8 of 10 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP
      A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
        (a) Amount beneficially owned:  1,506,422
        (b) Percent of class:  2.44%.  The percentage set forth in this Schedule 13G/A is calculated based upon, 61,822,554 shares of Common Stock as of October 31, 2023 as reported to be outstanding in the Company’s Quarterly Report on Form 10-Q for the Quarterly Period ended September 30, 2023 and filed with the Securities and Exchange Commission on November 7, 2023.
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  1,506,422
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  1,506,422
    ACP has the power to dispose of and the power to vote the Common Stock beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP’s operations. Neither ACPGP nor ACA directly own any Common Stock.  By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the “Act”), ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.

     

     

    CUSIP No. 35961610913G/APage 9 of 10 Pages

     

     

      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  1,506,422
        (b) Percent of class:  2.44%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  1,506,422
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  1,506,422

     

    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the Common Stock beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the shares beneficially owned by ACP.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 35961610913G/APage 10 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 7, 2024

     

    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL ADVISORS, L.L.C.  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ROBERT ATCHINSON  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    PHILLIP GROSS  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

    Get the next $FULC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FULC

    DatePrice TargetRatingAnalyst
    1/12/2026$20.00Overweight
    Analyst
    11/24/2025Buy
    Truist
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    9/12/2024$4.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $FULC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 70,000 options to purc

    2/6/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees 30,400 options to

    1/9/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulc

    1/7/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    SEC Filings

    View All

    Fulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    1/12/26 8:18:27 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    12/10/25 9:36:53 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Fulcrum Therapeutics Inc.

    424B5 - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    12/10/25 9:34:32 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Fulcrum Therapeutics

    Truist initiated coverage of Fulcrum Therapeutics with a rating of Buy

    11/24/25 8:30:36 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously

    7/29/25 11:36:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

    4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:15:06 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Musso Alan A

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:10:05 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:10:03 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    3/5/24 4:15:17 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

    CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details

    10/22/25 8:54:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment

    7/29/25 6:45:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Assistant Professor at UVA School of Medicine Inova Campus, and Dr. Wally Smith, Director at the VC

    7/28/25 4:01:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/12/24 3:51:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Leadership Updates

    Live Leadership Updates

    View All

    Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    8/19/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as

    3/18/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record

    8/3/23 6:55:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care